Trogenix
Biotech · Edinburgh, GB
Biotech che combina vettori AAV e super-enhancer sintetici per terapie oncologiche contro tumori solidi aggressivi.
Funding history
| Date | Round | Amount |
|---|
| Oct 2025 | Series A Trogenix raised an €80 million Series A led by IQ Capital for its 'Trojan horse' cancer therapies. | $92.8M |
Investors
4BIO CapitalBrain Tumor Investment FundCalculus CapitalCancer Research HorizonsEli LillyIQ CapitalLongeVCMeltwind
Similar companies in Biotech
Explore funding flow on EquityFlow →